FINWIRES · TerminalLIVE
FINWIRES

市場の動向:スペインのレプソル、ベネズエラの石油資産の支配権奪還に向けた合意に近づく

-- レプソル(REP.MC)は、南米ベネズエラ政府との新たな合意に基づき、同国における石油資産の操業権を回復する見込みで、早ければ木曜日にも発表される予定だと、ロンドンのフィナンシャル・タイムズ紙が同日報じた。 この合意に基づき、スペインのエネルギー大手レプソルは、ベネズエラ事業の生産量を3年以内に3倍に増やす計画だと、関係筋が同紙に語った。 また、レプソルは、ベネズエラ政府による過去の債務不履行問題を回避するため、「保証付き」支払いメカニズムの構築も盛り込む予定だと、同紙は付け加えた。 レプソルは、MTニュースワイヤーズからのコメント要請にすぐには応じなかった。 (マーケットチャッターのニュースは、世界中の市場専門家との会話に基づいています。この情報は信頼できる情報源に基づいていると考えられますが、噂や憶測が含まれる可能性があります。正確性は保証されません。)

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703